Aarti Drugs posts 16% PAT growth, new MD takes charge

Aarti Drugs Ltd has recently reported strong financial results with FY26 consolidated PAT rising 16% to ₹195 crore, alongside a leadership transition where Adhish P. Patil has taken over as Managing Director effective October 2026. The stock has shown bullish technical momentum, trading around ₹379–402 with recent gains of over 6%. 📊 Latest Financial Highlights FY26 Consolidated PAT: ₹195 crore, up 16% YoY from ₹168 crore. Revenue: ₹2,568 crore, up 6.8% YoY. EBITDA: ₹312 crore, despite margin pressures from start-up costs and geopolitical headwinds. Q1FY27 Revenue: ₹703.6 crore, up 19% YoY, driven by API price hikes and volume growth. Q1FY27 EBITDA: ₹96.9 crore, margins expanded to 13.8%. 🏢 Corporate & Management Updates Leadership Transition: Shri Prakash M. Patil retired as Chairman, MD & CEO on 30 Sept 2026. Adhish P. Patil promoted from CFO to MD effective 1 Oct 2026. Shri Rashesh C. Gogri appointed as Chairman. Performance Stock Option Plan (PSOP 2026): Approved at AGM with 84.8% shareholder support, though institutional investors voted 99.7% against. Up to 8 lakh performance stock options authorized. 📈 Stock Performance & Technicals Latest Price: Around ₹402.25 (NSE/BSE). Day Range: ₹380.85 – ₹404.80. 52-Week Range: ₹318.95 – ₹534.00. Recent Move: +6.04% on 27 Oct 2026. Technical Outlook: Momentum shifted from sideways to mildly bullish. Daily moving averages turning positive. Weekly MACD mildly bearish, monthly MACD mildly bullish (mixed signals). RSI neutral, suggesting room for directional movement. ⚠️ Risks & Watchpoints Geopolitical Risks: Raw material supply chain pressures, especially ammonia. Institutional Resistance: Strong opposition to PSOP 2026 may signal governance concerns. Market Volatility: Despite PAT growth, margins remain sensitive to raw material inflation.